University of Minnesota. Driven to Discover.
A trial at the end of Liberia's Ebola outbreak shows 2 candidate vaccines posed no major safety concerns and triggered immune responses that lasted at least a year.
The phase 2 trials will enroll more than 5,000 adults and kids in Guinea and Liberia.
As cases drop slightly, vaccine trials suffer from lack of patients. Also, the NIH announces a trial involving survivors.
The findings clear the way for the next step, which may require a change in venue.
The virus may be more stable than a study in August found.
Another American health worker has been infected with Ebola in West Africa's outbreak region.
With its Mar 7 launch date, the trial's main goal is to see if ring vaccination can knock down Ebola hot spots.
Steeply dropping cases, though, may cause the NIAID to vary from the original trial design.
A clinical trial of 2 Ebola vaccine candidates was launched today near Liberia's capital, but falling case numbers may pose problems.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.